10 results · 20ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

ARTSMedia Semen Wash Medium

FDA 510(k)
FDA Class 2 ·Obstetrics/Gynecology

SKYHAWK

FDA UDI
Orthofix US LLC·18257200087297·T-HANDLE, TORQUE LIMITING DRIVER

STRYKER STERI-SHIELD FLYTE HYBRID TOGAS

FDA 510(k)
FDA Class 2 ·General, Plastic Surgery

PHOTOSILK PULSED LIGHT SYSTEM

FDA 510(k)
FDA Class 2 ·General, Plastic Surgery

ENDOWRIST

FDA Adverse Event
Malfunction ·INTUITIVE SURGICAL, INC·Product code NAY·January 30, 2026

LIGACLIP ENDOSCOPIC ROTATING MULTIPLE CLIP APPLIER 20 MEDIUM - LARGE TITANIUM LI

FDA Adverse Event
Injury ·ETHICON ENDO-SURGERY, LLC·Product code FZP·November 21, 2008

ENDEAVOR SPRINT RX CORONARY STENT SYSTEM

FDA Adverse Event
Malfunction ·MEDTRONIC IRELAND·Product code NIQ·August 16, 2011

PROGUIDE CHRONIC DIALYSIS CATHETER

FDA Adverse Event
Malfunction ·MERIT MEDICAL SYSTEMS, INC.·Product code MSD·July 18, 2013

ENDOWRIST

FDA Adverse Event
Malfunction ·INTUITIVE SURGICAL, INC·Product code NAY·May 30, 2025

Boston Scientific TELIGEN, Implantable Cardiac Defibrillator models E102, E110, the following models are not available in the US: models E103, E111, F102, F103, F110, F111. Sterilized using ethylene oxide. Product Usage: This family of implantable cardioverter defibrillators (ICDs) provide a variety of therapies including: -Ventricular tachyarrhythmia therapy, which is used to treat rhythms associated with sudden cardiac death such as VT and VF; -Bradycardia pacing, including adaptive rate pacing, to detect and treat bradyarrhythmias and to provide cardiac rate support after defibrillation therapy. Boston Scientific implantable cardioverter defibrillators (ICDs) are indicated to provide ventricular antitachycardia pacing (ATP) and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias

FDA Enforcement
Class II ·Terminated·Boston Scientific CRM Corp·October 29, 2014